In addition, some studies, such as AIM-HIGH and ACCORD (Action to Control Cardiovascular Risk in Diabetes) (10), suggest possible benefit of add-on therapy for patients with high triglyceride levels and low HDL-C levels, which are markers of remnant lipoprotein cholesterol. A follow-up non–HDL-C goal could guide the treatment of these patients. In fact, add-on therapy to optimize atherogenic cholesterol levels in high-risk patients is compatible with the guideline advice for familial hyperlipidemia that “nonstatin cholesterol-lowering medications are often needed to lower LDL-C to acceptable levels” (2). Our view is that risk- and lipid-based paradigms are not mutually exclusive and could be complementary. At baseline, obtaining the most accurate assessment of risk is crucial in deciding whom to treat, whereas in follow-up, lipid measurements can serve as a marker of therapeutic response, promote adherence, motivate lifestyle improvements, and guide discussions about add-on pharmacologic therapy for patients who are clearly established as high-risk.